- Chimerix (CMRX) initiates dosing in a Phase 3 study of the oral nucleotide analog lipid-conjugate brincidofovir in patients with cytomegalovirus infection.
- Existing antiviral therapies for the infection (which affects hematopoietic cell transplant recipients) carry the risk of "significant hematologic and renal toxicities."
- No approved therapy for the prevention of the infection in hematopoietic cell transplant recipients exists. (PR)
Chimerix commences Phase 3 trial of brincidofovir
Sep 9 2013, 07:46 ET